|
Indications and Dosage
Oral
Depression Adult: 200-300 mg daily in 2-3 divided doses, up to 600 mg daily if tolerated.
Elderly: Initial 100 mg daily, increase very carefully if necessary. |
|
Renal Impairment
Initial 100 mg daily, increase very carefully if necessary.
|
|
Hepatic Impairment
Initial 100 mg daily, increase very carefully if necessary.
|
|
Contraindications
Lactation. Porphyria, recent MI.
|
|
Special Precautions
Pregnancy. Hepatic or renal impairment; CV disease; epilepsy. Monitor closely until depression improves due to suicidal risk in depressed patients. Withdraw gradually to reduce withdrawal symptoms. May precipitate migraine attacks. May impair ability to drive or operate machinery. Stop 48 hr before general anaesthesia.
|
|
Adverse Reactions
Headache, nausea, vomiting, drowsiness, tremor, ataxia, antimuscarinic side effects (e.g. dry mouth, constipation); musculoskeletal pain; mild hypertension; skin rashes; convulsions; jaundice. Increase in LFT.
|
|
Drug Interactions
May decrease antihypertensive effects with antihypertensives. Increased CNS depressant effects with alcohol. Increased the anticoagulant effects of acenocoumarol.
Potentially Fatal: Increased carbamazepine, theophylline, aminophylline, phenytoin levels and thus increased risk of toxicity. Do not admin viloxazine for at least 14 days after discontinuation from MAOI and MAOI to be given at least 1 wk after discontinuation from viloxazine. |
|
Action
Description: Viloxazine, a bicyclic antidepressant, inhibits noradrenaline reuptake and enhance serotonin release from neuronal stores. It has fewer antimuscarinic side effects compared to tricyclic antidepressants.
Pharmacokinetics: Absorption: Absorbed readily from GI tract. Distribution: Distributed in breastmilk. Metabolism: Extensively metabolised. Plasma half life: 2-5 hr. Excretion: Excreted in urine as free or conjugated metabolites. |
|
MIMS Class
|
Sign Out
